501 results on '"Pigneux, Arnaud"'
Search Results
2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
3. Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
4. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
5. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
6. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
7. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
8. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
9. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study
10. Cost comparison of post-remission strategies in younger and older AML patients in France
11. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
12. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
13. Overlapping features of therapy-related and de novo NPM1-mutated AML
14. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
15. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
16. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
17. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
18. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
19. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
20. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
21. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
22. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
23. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
24. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study
25. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
26. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
27. Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts
28. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT
29. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
30. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
31. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
32. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
33. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
34. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
35. AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy
36. Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA
37. Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
38. Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
39. Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy.
40. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
41. Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors
42. Transient Grades 3 to 4 Acute Hepatitis Is a Common Complication of Rabbit Antithymocyte Globulin (Thymoglobulin) Administered before Allogeneic Stem Cell Transplantation
43. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
44. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
45. Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
46. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
47. Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
48. Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
49. Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
50. Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.